Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.

Item

http://www.wikidata.org/entity/Q38271733

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.

@en

type

Item

label

Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.

@en

prefLabel

Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.

@en

P1476

Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.

@en

P2093

A P Stefanoyiannis

http://www.w3.org/2001/XMLSchema#string

E P Efstathopoulos

http://www.w3.org/2001/XMLSchema#string

G C Nikiforidis

http://www.w3.org/2001/XMLSchema#string

M T Chalkia

http://www.w3.org/2001/XMLSchema#string

S N Chatziioannou

http://www.w3.org/2001/XMLSchema#string

W H Round

http://www.w3.org/2001/XMLSchema#string

P2860

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Activity quantification combining conjugate-view planar scintigraphies and SPECT/CT data for patient-specific 3-D dosimetry in radionuclide therapy.

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Update: the case for patient-specific dosimetry in radionuclide therapy.

P2888

s13246-014-0312-7

P304

7-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13246-014-0312-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1049714791

http://www.w3.org/2001/XMLSchema#string

P698

25427548

http://www.w3.org/2001/XMLSchema#string